VolitionRXUS9286611077VNRXVNRX
Financials
Market Cap
$69.76M5Y beta
1.29EPS (TTM)
-$0.504Free Float
62.44MRevenue (TTM)
$775.30KEBITDA (TTM)
-$34.58MFree Cashflow (TTM)
-$19.15MPricing
Analyst Ratings
The price target is $3.725 and the stock is covered by 4 analysts.
Buy
3
Hold
1
Sell
0
Information
VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.